Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study

• Main Authors: Marco Ceccanti (Author), Laura Libonati (Author), Gabriele Ruffolo (Author), Pierangelo Cifelli (Author), Federica Moret (Author), Vittorio Frasca (Author), Eleonora Palma (Author), Maurizio Inghilleri (Author), Chiara Cambieri (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: 3,4-diaminopyridine (3,4-DAP) can lead to clinical and electrophysiological improvement in myasthenic syndrome; it may thus represent a valuable therapeutic option for patients intolerant to pyridostigmine.Objective: to assess 3,4-diaminopyridine (3,4-DAP) effects and tolerability in pat...